Cite
HARVARD Citation
Udata, C. et al. (2017). A Mechanism‐Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development. Journal of clinical pharmacology. pp. 855-864. [Online].